Proposed Biotech Investment National Security Act may protect US firms but contains loophole aiding Chinese competition

A bipartisan bill called the Biotech Investment National Security Act (BINSA) has been introduced in Congress to expand federal oversight of biotechnology activities, from drug development to biologics manufacturing and clinical research. The legislation builds on the earlier Comprehensive Outbound Investment National Security (COINS) Act and aims to safeguard U.S. national‑security interests in medical innovation.

Supporters, including Rep. John Moolenaar, argue the measure is needed after multibillion‑dollar R&D and licensing deals between Pfizer, Bristol Myers Squibb and Chinese biotech firms. They claim such partnerships threaten the future of American pharmaceutical production.

Critics, however, point to a loophole that could allow companies to route work through third‑country partners, a practice dubbed “Eurowashing,” which would undermine the bill’s intent and still benefit Chinese competitors.

Executives at Optimapharm caution that the industry must chart a new geographic strategy before heavy‑handed legislation forces a less favorable outcome.